Literature DB >> 10666337

Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.

I G Cowell1, A L Okorokov, S A Cutts, K Padget, M Bell, J Milner, C A Austin.   

Abstract

The p53 tumor suppressor protein is a critical regulator of cell cycle progression and apoptosis following exposure of cells to DNA damaging agents such as ionizing radiation or anticancer drugs. An important group of anticancer drugs, including compounds such as etoposide and doxorubicin (Adriamycin), interacts with DNA topoisomerase II (topo II), causing the accumulation of enzyme-DNA adducts that ultimately lead to double-strand breaks and cell death via apoptosis. Human topo IIbeta has previously been shown to interact with p53, and we have extended this analysis to show that both topo IIalpha and IIbeta interact with p53 in vivo and in vitro. Furthermore, we show that the regulatory C-terminal basic region of p53 (residues 364-393) is necessary and sufficient for interaction with DNA topo II. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666337     DOI: 10.1006/excr.1999.4772

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  13 in total

1.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.

Authors:  Yi Lisa Lyu; James C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-28       Impact factor: 11.205

Review 2.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

3.  Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network.

Authors:  Yi-Wen Chang; Chia-Lang Hsu; Cheng-Wei Tang; Xiang-Jun Chen; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Mol Cell Proteomics       Date:  2020-08-11       Impact factor: 5.911

4.  p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.

Authors:  Jie Li; Ping-Yuan Wang; Nathaniel A Long; Jie Zhuang; Danielle A Springer; Jizhong Zou; Yongshun Lin; Christopher K E Bleck; Ji-Hoon Park; Ju-Gyeong Kang; Paul M Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-05       Impact factor: 11.205

5.  Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.

Authors:  J Damrot; T Nübel; B Epe; W P Roos; B Kaina; G Fritz
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

6.  Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.

Authors:  Yang Wang; Yoshiaki Azuma; David Moore; Neil Osheroff; Kristi L Neufeld
Journal:  Mol Biol Cell       Date:  2008-07-16       Impact factor: 4.138

7.  Topoisomerase II β Gene Specific siRNA Delivery by Nanoparticles Prepared with c-ter Apotransferrin and its Effect on HIV-1 Replication.

Authors:  Lokeswara Bala Krishna Sunnam; Anand K Kondapi
Journal:  Mol Biotechnol       Date:  2021-05-16       Impact factor: 2.695

8.  Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin.

Authors:  André Landin Malt; Julie Cagliero; Kevin Legent; Joël Silber; Alain Zider; Domenico Flagiello
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

9.  Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.

Authors:  Jessica P Wyles; Zhongqin Wu; Shelagh E L Mirski; Susan P C Cole
Journal:  Nucleic Acids Res       Date:  2007-06-12       Impact factor: 16.971

10.  Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells.

Authors:  Catriona M Manville; Kayleigh Smith; Zbyslaw Sondka; Holly Rance; Simon Cockell; Ian G Cowell; Ka Cheong Lee; Nicholas J Morris; Kay Padget; Graham H Jackson; Caroline A Austin
Journal:  Biol Open       Date:  2015-10-12       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.